Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Lymphocyte activation gene 3 protein (LAG3) · developed by MacroGenics
Tebotelimab is a humanized, Fc-bearing antibody-like protein that binds both PD-1 and LAG-3, immune checkpoint molecules expressed on T cells. Dual blockade of these pathways is intended to enhance cytotoxic T-lymphocyte responses against tumor cells. It is being studied in advanced solid tumors, hematologic neoplasms, and several carcinomas including ovarian, lung, gastric, breast and biliary tract cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04082364 | Phase 2/3 | Gastric Cancer | Completed | MGNX |
| NCT04212221 | Phase 1/2 | Advanced Hepatocellular Carcinoma (HCC) | Terminated | ZLAB |
| NCT04653038 | Phase 1 | Unresectable, Recurrent or Metastatic Melanoma | Terminated | ZLAB |
| NCT04178460 | Phase 1 | Gastric Cancer | Terminated | ZLAB |
| NCT03219268 | Phase 1 | Advanced Solid Tumors | Completed | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsBiliary Tract CarcinomaCervical CancerCholangiocarcinomaGastric CancerGastroesophageal Junction CancerHematologic NeoplasmsHER2-positive Advanced Solid TumorsHER2-positive Gastric CancerNon Small Cell Lung CancerOvarian CancerSmall-cell Lung CancerSquamous Cell Carcinoma of Head and NeckTNBC - Triple-Negative Breast Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →